Get Well Chemist And Druggist Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-07-2024
- Paid Up Capital ₹ 0.65 M
as on 05-07-2024
- Company Age 21 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.01 M
as on 05-07-2024
- Revenue -7.71%
(FY 2022)
- Profit -332.10%
(FY 2022)
- Ebitda 165.58%
(FY 2022)
- Net Worth -11.95%
(FY 2022)
- Total Assets -7.45%
(FY 2022)
About Get Well Chemist And Druggist
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.65 M.
The company currently has active open charges totaling ₹1.01 M.
Saptarshi Ghosh, Sarbani Ghosh, Indrani Ghatak, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51397WB2003PTC096077
- Company No.
096077
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Apr 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Get Well Chemist And Druggist?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saptarshi Ghosh  | Director | 22-Apr-2003 | Current |
| Sarbani Ghosh | Director | 22-Apr-2003 | Current |
| Indrani Ghatak | Director | 22-Apr-2003 | Current |
| Sumita Ghatak | Director | 22-Apr-2003 | Current |
| Sarbajit Ghatak | Director | 22-Apr-2003 | Current |
Financial Performance of Get Well Chemist And Druggist.
Get Well Chemist And Druggist Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 7.71% decrease. The company also saw a substantial fall in profitability, with a 332.1% decrease in profit. The company's net worth observed a substantial decline by a decrease of 11.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Get Well Chemist And Druggist?
In 2021, Get Well Chemist And Druggist had a promoter holding of 64.98% and a public holding of 35.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Phiz Technologies & Solutions Private LimitedActive 17 years 1 month
Sarbani Ghosh is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Nov 2020 | ₹1.01 M | Open |
How Many Employees Work at Get Well Chemist And Druggist?
Unlock and access historical data on people associated with Get Well Chemist And Druggist, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Get Well Chemist And Druggist, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Get Well Chemist And Druggist's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
